Biosimilar Preferred Drug List (PDL) 2026 Update
Effective January 1, 2026, the Department will add preferred and non-preferred drugs to the Biosimilar PDL.
Preferred drugs added:
- Q 9996 Ustekinumab-ttwe SubQ
- Q 99976 Ustekinumab-ttwe I.V.
- Q5140 - adalimumab-fkjp
- Q5142 -SIMLANDI, adalimumad ryvk
Change from preferred to non-preferred drug: